Performance of the SureScreen Diagnostics COVID-19 antibody rapid test in comparison with three automated immunoassays
Copyright © 2023 Elsevier Inc. All rights reserved..
Lateral flow immunoassays (LFIA) for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies are used for population surveillance and potentially individual risk assessment. The performance of the SureScreen Diagnostics LFIA targeting the spike protein was evaluated in comparison with 3 automated assays (Abbott Alinity-i SARS-CoV-2 IgG, DiaSorin Liaison® SARS-CoV-2 S1/S2 IgG, Wantai SARS-CoV-2 Ab ELISA). We assessed sensitivity using 110 serum samples from PCR confirmed COVID-19 infected patients. Specificity was evaluated using 120 prepandemic samples, including potential cross-reactive antibodies samples. Sensitivity ranged between 93.3% and 98.7% on samples collected >14 days postsymptom onset. All assays achieved a specificity >98%. Moreover, its performance seems not to be affected by Alpha, Beta or Delta variants over a wide range of antibody titers. The latter showed a very good agreement with the Wantai and the Abbott assays and a substantial agreement with the DiaSorin assay. Our data demonstrate the good clinical performance of the SureScreen Diagnostics LFIA for SARS-CoV-2 seroprevalence screening.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:105 |
|---|---|
| Enthalten in: |
Diagnostic microbiology and infectious disease - 105(2023), 4 vom: 15. Apr., Seite 115900 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mafi, Sarah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 21.03.2023 Date Revised 21.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diagmicrobio.2023.115900 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352269820 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352269820 | ||
| 003 | DE-627 | ||
| 005 | 20231226053330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diagmicrobio.2023.115900 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352269820 | ||
| 035 | |a (NLM)36716586 | ||
| 035 | |a (PII)S0732-8893(23)00010-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mafi, Sarah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Performance of the SureScreen Diagnostics COVID-19 antibody rapid test in comparison with three automated immunoassays |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2023 | ||
| 500 | |a Date Revised 21.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Lateral flow immunoassays (LFIA) for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies are used for population surveillance and potentially individual risk assessment. The performance of the SureScreen Diagnostics LFIA targeting the spike protein was evaluated in comparison with 3 automated assays (Abbott Alinity-i SARS-CoV-2 IgG, DiaSorin Liaison® SARS-CoV-2 S1/S2 IgG, Wantai SARS-CoV-2 Ab ELISA). We assessed sensitivity using 110 serum samples from PCR confirmed COVID-19 infected patients. Specificity was evaluated using 120 prepandemic samples, including potential cross-reactive antibodies samples. Sensitivity ranged between 93.3% and 98.7% on samples collected >14 days postsymptom onset. All assays achieved a specificity >98%. Moreover, its performance seems not to be affected by Alpha, Beta or Delta variants over a wide range of antibody titers. The latter showed a very good agreement with the Wantai and the Abbott assays and a substantial agreement with the DiaSorin assay. Our data demonstrate the good clinical performance of the SureScreen Diagnostics LFIA for SARS-CoV-2 seroprevalence screening | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Lateral Flow Immunoassays (LFIA) | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SureScreen Diagnostics | |
| 650 | 4 | |a serology | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Rogez, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Darreye, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Alain, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Hantz, Sébastien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostic microbiology and infectious disease |d 1986 |g 105(2023), 4 vom: 15. Apr., Seite 115900 |w (DE-627)NLM01262845X |x 1879-0070 |7 nnns |
| 773 | 1 | 8 | |g volume:105 |g year:2023 |g number:4 |g day:15 |g month:04 |g pages:115900 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diagmicrobio.2023.115900 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2023 |e 4 |b 15 |c 04 |h 115900 | ||